Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.

Kister I, Chamot E, Bacon JH, Cutter G, Herbert J; New York State Multiple Sclerosis Consortium.

Mult Scler. 2011 Jun;17(6):725-33. doi: 10.1177/1352458510396269. Epub 2011 Jan 26.

PMID:
21270059
2.

Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.

Gava G, Bartolomei I, Costantino A, Berra M, Venturoli S, Salvi F, Meriggiola MC.

Fertil Steril. 2014 Jul;102(1):116-22. doi: 10.1016/j.fertnstert.2014.03.054. Epub 2014 Apr 29.

PMID:
24794311
3.

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.

Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12.

PMID:
21228027
4.

Predictive value of clinical characteristics for 'benign' multiple sclerosis.

Ramsaransing GS, De Keyser J.

Eur J Neurol. 2007 Aug;14(8):885-9.

PMID:
17662009
5.

Rapid disease course in African Americans with multiple sclerosis.

Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman AD, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer FE 3rd, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J.

Neurology. 2010 Jul 20;75(3):217-23. doi: 10.1212/WNL.0b013e3181e8e72a.

PMID:
20644149
6.

Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.

Enzinger C, Fuchs S, Pichler A, Wallner-Blazek M, Khalil M, Langkammer C, Ropele S, Fazekas F.

Mult Scler. 2011 Jun;17(6):695-701. doi: 10.1177/1352458510394454. Epub 2011 Jan 12.

PMID:
21228028
7.

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC, Leyva L, Oliver B, de Ramón E, Luque G, Fernández V.

Mult Scler. 2011 Feb;17(2):192-7. doi: 10.1177/1352458510385507. Epub 2010 Nov 18.

PMID:
21088044
8.

Plasma pentosidine: a potential biomarker in the management of multiple sclerosis.

Sternberg Z, Hennies C, Sternberg D, Bistulfi GL, Kazim L, Benedict RH, Chadha K, Leung C, Weinstock-Guttman B, Munschauer F.

Mult Scler. 2011 Feb;17(2):157-63. doi: 10.1177/1352458510384123. Epub 2010 Oct 21.

PMID:
20965962
9.

Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada.

Saeedi J, Rieckmann P, Yee I, Tremlett H; UBC MS clinic neurologists.

Mult Scler. 2012 Sep;18(9):1239-43. doi: 10.1177/1352458512436595. Epub 2012 Mar 1.

PMID:
22383230
10.

Increasing age at disability milestones among MS patients in the MSBase Registry.

Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators.

J Neurol Sci. 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14.

PMID:
22507751
11.

Olfactory dysfunction in multiple sclerosis: association with secondary progression.

Silva AM, Santos E, Moreira I, Bettencourt A, Coutinho E, Gonçalves A, Pinto C, Montalban X, Cavaco S.

Mult Scler. 2012 May;18(5):616-21. doi: 10.1177/1352458511427156. Epub 2011 Oct 21.

PMID:
22020420
12.

Association between MRI parameters and the MS severity scale: a 12 year follow-up study.

Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F.

Mult Scler. 2009 May;15(5):632-7. doi: 10.1177/1352458509102617.

PMID:
19389751
13.

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.

Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.

Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.

PMID:
18184917
14.

Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.

Stauch C, Reiber H, Rauchenzauner M, Strasak A, Pohl D, Hanefeld F, Gärtner J, Rostásy KM.

Mult Scler. 2011 Mar;17(3):327-34. doi: 10.1177/1352458510388543. Epub 2010 Dec 1.

PMID:
21123302
15.

Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.

Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Karahalios G, Sfagos C.

J Neurochem. 2009 Jan;108(1):158-64. doi: 10.1111/j.1471-4159.2008.05750.x. Epub 2008 Nov 12.

16.

T2 lesions and rate of progression of disability in multiple sclerosis.

Mostert JP, Koch MW, Steen C, Heersema DJ, De Groot JC, De Keyser J.

Eur J Neurol. 2010 Dec;17(12):1471-5. doi: 10.1111/j.1468-1331.2010.03093.x.

PMID:
20500805
17.

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group.

Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.

PMID:
19542262
18.

Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.

Guerrero AL, Laherrán E, Gutiérrez F, Martín-Polo J, Iglesias F, Alcázar C, Peralta J, Rostami P.

Acta Neurol Scand. 2008 Jan;117(1):21-5. Epub 2007 Sep 19.

PMID:
17883422
19.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
20.

Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.

Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C, Lugaresi A, Merelli E, Meucci G, Motti L, Tola MR, Scarpini E, Repice AM, Massacesi L, Saccardi R; Italian BMT Study Group.

Mult Scler. 2012 Jun;18(6):835-42. doi: 10.1177/1352458511429320. Epub 2011 Nov 29.

PMID:
22127896

Supplemental Content

Support Center